Pyxis Oncology, Inc. (PYXS)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D
PYXS's main value driver is MICVO. This is an oncology drug candidate that could be useful for killing cancerous cells. MICVO's early data has been promising, but PYXS still has to find an adequate dose that's safe and effective. Fortunately, PYXS's recent raise helps their financing in the near term and should be enough for them to reach important clinical milestones with MICVO.
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Madelyn D. Purcell Pfizer Inc | 7.03M | $10.97M | $11.67M | $703,277 | 6.41% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 42,455 | $80,664.5 | $75,994.45 | -$4,670.05 | -5.79% |
 Loryn J. Mischke University Of Chicago | 48,731 | $65,300 | $80,893.46 | $15,593.46 | 23.88% |
 Point72 Asset Management LP Point72 Asset Management LP | 37,092 | $46,470.23 | $66,765.6 | $20,295.37 | 43.67% |
 Kyle P. Smith NewEdge Wealth LLC | 116,006 | $425,735.69 | $205,910.65 | -$219,825.04 | -51.63% |
Pyxis Oncology, Inc. (PYXS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pyxis Oncology, Inc. ever had a stock split?
Pyxis Oncology, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Thomas Civik CEO | NASDAQ (NGS) Exchange | 747324101 CUSIP |
| US Country | 56 Employees | - Last Dividend | - Last Split | 8 Oct 2021 IPO Date |
Overview
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for the treatment of various types of cancers. With a focus on immunology and precision medicine, Pyxis Oncology aims to address the unmet needs in oncology care by developing groundbreaking treatments. Founded in 2018, the company is headquartered in the notable biotech hub of Cambridge, Massachusetts, emphasizing its commitment to cutting-edge research and development in the battle against cancer.
Products and Services
Pyxis Oncology, Inc. has an impressive pipeline of product candidates in various stages of clinical development, each targeting different forms of solid tumors through distinct mechanisms. These include:
- PYX-106: This investigational product is a fully human immunoglobulin G1 isotype siglec-15 targeting antibody. It is currently in Phase 1 clinical trials, focusing on treating a wide array of solid tumors such as non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The goal of PYX-106 is to harness the body's immune response to target and destroy cancer cells effectively.
- PYX-201: As an antibody drug conjugate, PYX-201 represents a next-generation approach to cancer treatment. This investigational product is a human immunoglobulin G1 isotype that has been site-specifically conjugated to elevate its ability to target solid tumors. Currently, PYX-201 is undergoing Phase 1 clinical trials to assess its efficacy against several types of solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. PYX-201 exemplifies Pyxis Oncology's commitment to developing precise, targeted therapies that minimize harm to healthy tissues while maximizing the potential to treat cancer effectively.
Contact Information
